Combination drug therapy for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new pill (calderasib) combined with an immunotherapy drug (pembrolizumab) for people with a specific type of advanced non-small cell lung cancer. It aims to see if the combination can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer (the most common type) that has spread or is advanced.
- Your cancer has a specific gene change called KRAS G12C and a protein marker (PD-L1) at a high level (at least 50%).
- You cannot have had chemotherapy or other treatments for this stage of lung cancer yet.
- You must be able to provide a tissue sample (biopsy) from your tumor for testing.
- You have not had radiation to your lungs within the past 6 months.
- You have no other active cancer or serious uncontrolled health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new drug combinations for people with advanced or metastatic non-small cell lung cancer (NSCLC). Depending on your PD-L1 level and genetic profile, you may be placed in one of three groups to see if these combinations help shrink or control your tumor.
This trial tests a new drug called calderasib (MK-1084) combined with other treatments for people with advanced non-small cell lung cancer that cannot be surgically removed. It aims to see if this combination works better than current options.
This trial tests a combination of two drugs—calderasib (a targeted therapy) and durvalumab (an immunotherapy)—for people with a specific type of advanced lung cancer that has a KRAS G12C mutation. The goal is to prevent the cancer from coming back after standard chemotherapy and radiation treatment.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This study tests a new pill combined with immunotherapy for people with advanced non-small cell lung cancer that has not been treated or has stopped responding to previous immunotherapy. The goal is to see if the combination is safe and helps shrink tumors.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.